Research ArticleOriginal Article

Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women

Fenfen Fu, Dongjie Zhang, Li Hu, Senthil Sundaram, Dingge Ying, Ying Zhang, Shuna Fu, Juan Zhang, Lu Yao, Ye Xu and Yuntao Xie
Cancer Biology & Medicine February 2022, 19 (2) 253-262; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0358

References

  1. 1.↵
    2. Fan L,
    3. Strasser-Weippl K,
    4. Li J-J,
    5. Louis JS,
    6. Finkelstein DM,
    7. Yu K-D, et al.
    Breast cancer in China. Lancet Oncol. 2014; 15: e279–89.
    OpenUrlCrossRefPubMed
  2. 2.
    2. Chen W,
    3. Zheng R,
    4. Baade PD,
    5. Zhang S,
    6. Zeng H,
    7. Bray F, et al.
    Cancer statistics in China, 2015: cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115–32.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Jiang X,
    3. Tang H,
    4. Chen T.
    Epidemiology of gynecologic cancers in China. J Gynecol Oncol. 2017; 29: e7.
  4. 4.↵
    2. Sun J,
    3. Meng H,
    4. Yao L,
    5. Lv M,
    6. Bai J,
    7. Zhang J, et al.
    Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res. 2017; 23: 6113–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Daly MB,
    3. Pilarski R,
    4. Yurgelun MB,
    5. Berry MP,
    6. Buys SS,
    7. Dickson P, et al.
    NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, Version 1.2020. J Natl Compr Cancer Netw. 2020; 18: 380–91.
    OpenUrl
  6. 6.↵
    2. Easton DF,
    3. Pharoah PDP,
    4. Antoniou AC,
    5. Tischkowitz M,
    6. Tavtigian SV,
    7. Nathanson KL, et al.
    Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015; 372: 2243–57.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Couch FJ,
    3. Shimelis H,
    4. Hu C,
    5. Hart SN,
    6. Polley EC,
    7. Na J, et al.
    Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 2017; 3: 1190.
    OpenUrl
  8. 8.↵
    2. Kurian AW,
    3. Hughes E,
    4. Handorf EA,
    5. Gutin A,
    6. Allen B,
    7. Hartman A-R, et al.
    Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in Women. JCO Precis Oncol. 2017; 1: 1–12.
    OpenUrl
  9. 9.↵
    2. Momozawa Y,
    3. Iwasaki Y,
    4. Parsons MT,
    5. Kamatani Y,
    6. Takahashi A,
    7. Tamura C, et al.
    Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018; 9: 4083.
    OpenUrlCrossRefPubMed
  10. 10.
    2. Li J,
    3. Meeks H,
    4. Feng B-J,
    5. Healey S,
    6. Thorne H,
    7. Makunin I, et al.
    Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. J Med Genet. 2015; 53: 34–42.
    OpenUrl
  11. 11.↵
    2. Slavin TP,
    3. Maxwell KN,
    4. Lilyquist J,
    5. Vijai J,
    6. Neuhausen SL,
    7. Hart SN, et al.
    The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer. 2017; 3: 22.
    OpenUrl
  12. 12.↵
    2. Shimelis H,
    3. LaDuca H,
    4. Hu C,
    5. Hart SN,
    6. Na J,
    7. Thomas A, et al.
    Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst. 2018; 110: 855–62.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Consortium BCA,
    3. Dorling L,
    4. Carvalho S,
    5. Allen J,
    6. González-Neira A,
    7. Luccarini C, et al.
    Breast cancer risk genes — association analysis in more than 113,000 women. N Engl J Med. 2021; 384: 428–39.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Hu C,
    3. Hart SN,
    4. Gnanaolivu R,
    5. Huang H,
    6. Lee KY,
    7. Na J, et al.
    A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021; 384: 440–51.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Buys SS,
    3. Sandbach JF,
    4. Gammon A,
    5. Patel G,
    6. Kidd J,
    7. Brown KL, et al.
    A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017; 123: 1721–30.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Tung N,
    3. Lin NU,
    4. Kidd J,
    5. Allen BA,
    6. Singh N,
    7. Wenstrup RJ, et al.
    Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016; 34: 1460–8.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Zhang J,
    3. Sun J,
    4. Chen J,
    5. Yao L,
    6. Ouyang T,
    7. Li J, et al.
    Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. Breast Cancer Res Treat. 2016; 158: 455–62.
    OpenUrlCrossRef
  18. 18.
    2. Li J,
    3. Jing R,
    4. Wei H,
    5. Wang M,
    6. Xiaowei Q,
    7. Liu H, et al.
    Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. Int J Cancer. 2019; 144: 281–9.
    OpenUrl
  19. 19.
    2. Bhaskaran SP,
    3. Chandratre K,
    4. Gupta H,
    5. Zhang L,
    6. Wang X,
    7. Cui J, et al.
    Germline variation in BRCA1 / 2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients. Int J Cancer. 2019; 145: 962–73.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Fan Z,
    3. Ouyang T,
    4. Li J,
    5. Wang T,
    6. Fan Z,
    7. Fan T, et al.
    Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients. Breast Cancer Res Treat. 2018; 169: 59–67.
    OpenUrl
  21. 21.↵
    2. Yang Z,
    3. Ouyang T,
    4. Li J,
    5. Wang T,
    6. Fan Z,
    7. Fan T, et al.
    Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients. Breast Cancer Res Treat. 2019; 174: 639–47.
    OpenUrl
  22. 22.↵
    2. Wu Y,
    3. Ouyang T,
    4. Li J,
    5. Wang T,
    6. Fan Z,
    7. Fan T, et al.
    Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients. Breast Cancer Res Treat. 2019; 179: 605–14.
    OpenUrl
  23. 23.↵
    2. Rainville IR,
    3. Rana HQ.
    Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep. 2014; 16: 371.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Stratton MR,
    3. Rahman N.
    The emerging landscape of breast cancer susceptibility. Nat Genet. 2007; 40: 17–22.
    OpenUrl
  25. 25.↵
    2. Richards S,
    3. Aziz N,
    4. Bale S,
    5. Bick D,
    6. Das S,
    7. Gastier-Foster J, et al.
    Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405–23.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Kleibl Z,
    3. Kristensen VN.
    Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. Breast. 2016; 28: 136–44.
    OpenUrl
  27. 27.↵
    2. Hwang S-J,
    3. Lozano G,
    4. Amos CI,
    5. Strong LC.
    Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003; 72: 975–83.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.
    2. Hearle N,
    3. Schumacher V,
    4. Menko FH,
    5. Olschwang S,
    6. Boardman LA,
    7. Gille JJP, et al.
    Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006; 12: 3209–15.
    OpenUrlAbstract/FREE Full Text
  29. 29.
    2. Hansford S,
    3. Kaurah P,
    4. Li-Chang H,
    5. Woo M,
    6. Senz J,
    7. Pinheiro H, et al.
    Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015; 1: 23.
    OpenUrlPubMed
  30. 30.↵
    2. Tan M-H,
    3. Mester JL,
    4. Ngeow J,
    5. Rybicki LA,
    6. Orloff MS,
    7. Eng C.
    Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012; 18: 400–7.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Sheng S,
    3. Xu Y,
    4. Guo Y,
    5. Yao L,
    6. Hu L,
    7. Ouyang T, et al.
    Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. Int J Cancer. 2020; 146: 487–95.
    OpenUrl
  32. 32.↵
    2. Yang X,
    3. Leslie G,
    4. Doroszuk A,
    5. Schneider S,
    6. Allen J,
    7. Decker B, et al.
    Cancer risks associated with germline PALB2 pathogenic variants: an International study of 524 families. J Clin Oncol. 2019; 38: 674–85.
    OpenUrl
  33. 33.↵
    2. Kuchenbaecker KB,
    3. Hopper JL,
    4. Barnes DR,
    5. Phillips K-A,
    6. Mooij TM,
    7. Roos-Blom M-J, et al.
    Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017; 317: 2402.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Zhou J,
    3. Wang H,
    4. Fu F,
    5. Li Z,
    6. Feng Q,
    7. Wu W, et al.
    Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing. Cancer. 2020; 126: 3202–8.
    OpenUrlPubMed
  35. 35.↵
    2. Southey MC,
    3. Goldgar DE,
    4. Winqvist R,
    5. Pylkäs K,
    6. Couch F,
    7. Tischkowitz M, et al.
    PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016; 53: 800–11.
    OpenUrlAbstract/FREE Full Text
  36. 36.
    2. Goldgar DE,
    3. Healey S,
    4. Dowty JG,
    5. Silva LD,
    6. Chen X,
    7. Spurdle AB, et al.
    Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 2011; 13: R73.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. (UK) TBCSC,
    2. Renwick A,
    3. Thompson D,
    4. Seal S,
    5. Kelly P,
    6. Chagtai T, et al.
    ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006; 38: 873–5.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    2. Kilpivaara O,
    3. Vahteristo P,
    4. Falck J,
    5. Syrjäkoski K,
    6. Eerola H,
    7. Easton D, et al.
    CHEK2 variant I157T may be associated with increased breast cancer risk: CHEK2 1157T and breast cancer risk. Int J Cancer. 2004; 111: 543–7.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.
    Consortium CBCC-C. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004; 74: 1175–82.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    2. Meijers-Heijboer H,
    3. Ouweland A van den,
    4. Klijn J,
    5. Wasielewski M,
    6. Snoo A de,
    7. Oldenburg R, et al.
    Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002; 31: 55–9.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    2. Steffen J,
    3. Nowakowska D,
    4. Niwińska A,
    5. Czapczak D,
    6. Kluska A,
    7. Piątkowska M, et al.
    Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer. 2006; 119: 472–5.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    2. Zhang G,
    3. Zeng Y,
    4. Liu Z,
    5. Wei W.
    Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumor Biol. 2013; 34: 2753–7.
    OpenUrl
  43. 43.↵
    2. Yao L,
    3. Sun J,
    4. Zhang J,
    5. He Y,
    6. Ouyang T,
    7. Li J, et al.
    Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat. 2016; 156: 441–5.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords